Werfen successfully completes a new 5-year bond issue for €500 million

• Allocation among institutional investors followed a well attended two-day marketing exercise
• Funds will be used to partially repay the financing for the acquisition of Immucor

Werfen has successfully completed its second bond issue in the amount of €500 million maturing in five years. The notes are senior unsecured and will be listed on the regulated market of Euronext Dublin.

This is the first issue under the Euro Medium Term Notes (EMTN) Programme registered by the company in April 2023. Following the inaugural bond issue of €300 million in October 2021, the establishment of this program represents a strategic milestone for the company, enabling Werfen to consolidate its presence in capital markets and to increase its financial flexibility.

As with the inaugural deal, Werfen has obtained an issuer and notes rating of BBB- with stable outlook by Standard & Poor’s. Additionally, the company has received a second rating from Fitch Ratings, which also assigned a BBB- rating with positive outlook to Werfen and the notes.

In a very different market environment to its 2021 debut, the bond issue was priced with a coupon of 4.625% (issue price: 99.139%) after an intensive two-day marketing exercise with investors, where over 80 accounts have participated.

The quality of the demand and the granularity of the orderbook demonstrate market's confidence in Werfen, as well as the attractiveness of the in-vitro diagnostics sector.

BBVA, BNP Paribas, CaixaBank, and HSBC acted as Global Coordinators with Banco Sabadell, Bank of America, Citi, Deutsche Bank, Intesa SanPaolo, J.P. Morgan, Mediobanca, MUFG, Natixis, and UniCredit also serving as Joint Bookrunners.

Werfen announced that the proceeds of the bond will be used to repay the Bridge Loan tranche of the financing for the acquisition of Immucor with a first maturity scheduled for November 2023. In this way, within a very volatile market backdrop, Werfen extends its debt maturities leaving a comfortable maturity profile.

For any questions, please contact Investor Relations: ir@werfen.com